Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036

Semin Oncol. 1994 Oct;21(5):613-9.

Authors

M A Eisenberger¹, E D Crawford, M Wolf, B Blumenstein, D G McLeod, R Benson, F A Dorr, M Benson, J T Spaulding

Affiliation

¹ Division of Medical Oncology, Johns Hopkins Oncology Center (Mid-Atlantic Oncology Program and Southwest Oncology Group), Baltimore, MD 21287-8936.

PMID: 7939752

No abstract available

Publication types

Clinical Trial
Multicenter Study
Randomized Controlled Trial

MeSH terms

Clinical Trials as Topic*
Data Interpretation, Statistical
Humans
Male
Neoplasm Staging
Neoplasms, Hormone-Dependent / drug therapy
Neoplasms, Hormone-Dependent / mortality*
Neoplasms, Hormone-Dependent / pathology*
Prognosis
Proportional Hazards Models
Prostatic Neoplasms / drug therapy
Prostatic Neoplasms / mortality*
Prostatic Neoplasms / pathology*
Regression Analysis
Survival Analysis